A bigger dose: Why generic drug producers are bulking up (Financial Times)

By Andrew Jack From his headquarters just outside Tel Aviv, Shlomo Yanai, a former top general in the Israeli Defence Force, is plotting the next stage in his commercial career: a campaign to reinforce his company Teva's position as the world's biggest generic medicines group. Last week he unveiled a $7.5bn (£3.7bn, €4.7bn) takeover of Barr (LSE: BAG.L - news) , a US-based competitor, to create a group with more than 500 marketed products and annual sales of $11bn. Now he is mulling fresh transactions to extend his reach still further. "You are going to see more moves of this kind in the future," he says, as he revises a five-year plan that prior to the Barr deal already envisaged a doubling of Teva's size by 2012. "We would like to be one of the top three companies in all our key markets." His strategy reflects an... [read full story]